Goodwin Procter LLP and McCarter & English LLP have advised Q32 Bio Inc. Wilmer Cutler Pickering Hale and Dorr LLP has advised the underwriters. Q32 Bio...
Q32 Bio Announces $200 Million Public Offering of Shares and Pre-Funded Warrants
Hemab Therapeutics Closes Upsized Initial Public Offering on Nasdaq
Wilmer Cutler Pickering Hale and Dorr has advised Hemab Therapeutics Holdings, Inc. Goodwin Procter has advised the underwriters. Hemab Therapeutics Holdings, Inc., a clinical-stage biotechnology company,...
Day One Biopharmaceuticals to Acquire Mersana Therapeutics in Transaction Valued Up to $285 Million
Wilmer Cutler Pickering Hale and Dorr has advised Mersana Therapeutics. Fenwick & West has advised Day One Biopharmaceuticals. Wilson Sonsini Goodrich & Rosati advised Day One...
Apellis Pharmaceuticals Enters Capped Royalty Purchase Agreement with Sobi for Aspaveli
WilmerHale has advised Apellis Pharmaceuticals on the deal. Apellis Pharmaceuticals, Inc., a global biopharmaceutical company, has announced the execution of a capped royalty purchase agreement with...
Trevi Therapeutics Issues $115 Million Common Stock Offering
Wilmer Cutler Pickering Hale and Dorr advised Trevi Therapeutics, Inc., and Covington & Burling advised the underwriters. Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company,...
KALA BIO’s $10.75 Million Private Placement
Wilmer Cutler Pickering Hale and Dorr represented KALA BIO, Inc. in the transaction. KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company, announced it had entered into...
Nxu’s Merger with Verde Bioresins
Wilmer Cutler Pickering Hale and Dorr is representing Verde Bioresins, Inc. in the transaction, and Snell & Wilmer is representing Nxu Inc. Verde Bioresins, Inc., a...
Terns Pharmaceuticals’ $172.7 Million IPO
Wilmer Cutler Pickering Hale and Dorr and Cooley advised on Terns Pharmaceuticals, Inc. on the offering, and Davis Polk & Wardwell advised the underwriters. Terns Pharmaceuticals,...
Kymera Therapeutics’ $258.75 Million Common Stock Offering
Wilmer Cutler Pickering Hale and Dorr represented the underwriters. Kymera Therapeutics, Inc. (Nasdaq: KYMR) (Kymera), a clinical-stage biopharmaceutical company, announced its public offering of 2,830,533 shares...
Karyopharm’s Refinancing Transactions and Amended Royalty Agreement
Wilmer Cutler Pickering Hale and Dorr advised Karyopharm Therapeutics Inc. on the transactions. Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies,...
Wonder Group’s $103 Million Acquisition of Blue Apron
Fenwick & West represented Wonder Group in the transaction, and Wilmer Cutler Pickering Hale and Dorr represented Blue Apron Holdings. Wonder Group (“Wonder”) announced that it has...
Omeat’s $40 Million Funding Round
Wilmer Cutler Pickering Hale and Dorr represented Omeat Inc. in the transaction. Omeat Inc. announced it has secured $40 million in funding as it emerges from stealth...